Emerging corticosteroid agonists for the treatment of asthma

Bibliography

• Available from: http://www.ncbi.nlm.nih.gov/books/NBK12994/
   Google Scholar
• Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006;148(3):245-54
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009;3(5):235-43
   PubMedGoogle Scholar
• Barnes PJ. Corticosteroids, IgE, and atopy. J Clin Invest 2001;107(3):265-6
   PubMed Web of Science ®Google Scholar
• Brostjan C, Anrather J, Csizmadia V, et al. Glucocorticoids inhibit E-selectin expression by targeting NF-kappaB and not ATF/c-Jun. J Immunol 1997;158(8):3836-44
   PubMed Web of Science ®Google Scholar
• van Rensen EL, Straathof KC, Veselic-Charvat MA, et al. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999;54(5):403-8
   PubMed Web of Science ®Google Scholar
• Sin DD, Man J, Sharpe H, et al. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004;292(3):367-76
   PubMed Web of Science ®Google Scholar
• Lange P, Scharling H, Ulrik CS, Vestbo J. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax 2006;61(2):100-4
   PubMed Web of Science ®Google Scholar
• Djukanović R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145(3):669-74
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999;159(9):941-55
   PubMed Web of Science ®Google Scholar
• Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J 2014;8:59-65
   PubMedGoogle Scholar
• Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol 2010;49(3):239-48
   PubMed Web of Science ®Google Scholar
• McKeever T, Harrison TW, Hubbard R, Shaw D. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study. Chest 2013;144(6):1788-94
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68(11):1029-36
   PubMed Web of Science ®Google Scholar
• Chmelik F, Doughty A. Objective measurements of compliance in asthma treatment. Ann Allergy 1994;73(6):527-32
   PubMedGoogle Scholar
• Available from: http://www.who.int/respiratory/asthma/en/
   Google Scholar
• Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114(1):40-7
   PubMed Web of Science ®Google Scholar
• von Bülow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract 2014;2(6):759-67
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ginasthma.org/local/uploads/files/GINA_Pocket_2014_Jun11.pdf
   Google Scholar
• Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999;353(9171):2213-14
   PubMed Web of Science ®Google Scholar
• Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007;62(12):1043-9
   PubMed Web of Science ®Google Scholar
• Cowan DC, Cowan JO, Palmay R, et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010;65(5):384-90
   PubMed Web of Science ®Google Scholar
• Chalmers GW, Macleod KJ, Little SA, et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57(3):226-30
   PubMed Web of Science ®Google Scholar
• Tomlinson JE, McMahon AD, Chaudhuri R, et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005;60(4):282-7
   PubMed Web of Science ®Google Scholar
• Anderson WJ, Lipworth BJ. Does body mass index influence responsiveness to inhaled corticosteroids in persistent asthma? Ann Allergy Asthma Immunol 2012;108(4):237-42
   PubMed Web of Science ®Google Scholar
• Newman SP. Aerosol deposition considerations in inhalation therapy. Chest 1985;88(2 Suppl):152S-60S
   PubMed Web of Science ®Google Scholar
• Cohen J, Postma DS, Douma WR, et al. Particle size matters: diagnostics and treatment of small airways involvement in asthma. Eur Respir J 2011;37(3):532-40
   PubMed Web of Science ®Google Scholar
• Takeda T, Oga T, Niima A, et al. Relationship between small airway function and health status, dyspnea and disease control in asthma. Respiration 2010;80(2):120-6
   PubMed Web of Science ®Google Scholar
• Alfieri V, Aiello M, Pisi R, et al. Small airway dysfunction is associated to excessive bronchoconstriction in asthmatic patients. Respir Res 2014;15:86
   PubMed Web of Science ®Google Scholar
• Newman SP. A comparison of lung deposition patterns between different asthma inhalers. J Aerosol Med 1995;8(Suppl 3):S21-6
   PubMedGoogle Scholar
• O’Connell EJ. Efficacy of budesonide in moderate to severe asthma. Clin Ther 2002;24(6):887-905
   PubMed Web of Science ®Google Scholar
• Eigen H. Efficacy of budesonide in inhaled corticosteroid-naive patients and patients with mild persistent asthma. Clin Ther 2002;24(7):1035-48
   PubMed Web of Science ®Google Scholar
• Adams NP, Bestall JB, Jones PW. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2000(4):CD002738
   Google Scholar
• Adams NP, Bestall JC, Lasserson TJ, et al. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2008;(4):CD003135
   Google Scholar
• McCormack PL, Plosker GL. Inhaled mometasone furoate: A review of its use in persistent asthma in adults and adolescents. Drugs 2006;66(8):1151-68
   PubMed Web of Science ®Google Scholar
• Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007;293(3):L660-7
   PubMed Web of Science ®Google Scholar
• Kemp JP, Berkowitz RB, Miller SD, et al. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000;106(3):485-92
   PubMed Web of Science ®Google Scholar
• Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and healthrelated quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000;106:852-60
   PubMed Web of Science ®Google Scholar
• Bousquet J. Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma. Int J Clin Pract 2009;63(5):806-19
   PubMed Web of Science ®Google Scholar
• Zeidler M, Corren J, Tashkin DP. Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma. Curr Med Res Opin 2010;26(6):1295-305
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bleecker ER, Busse WW, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res 2011;12:160
   PubMed Web of Science ®Google Scholar
• Lötvall J, Bleecker ER, Busse WW, et al. Efficacy and safety of fluticasone furoate 100 Ug once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. Respir Med 2014;108(1):41-9
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bateman ED, Busse WW, et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respir Res 2011;12:132
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Woodcock A, Bleecker ER, et al. Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. Respir Res 2014;15:88
   PubMed Web of Science ®Google Scholar
• Bateman ED, Bleecker ER, Lötvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med 2012;106(5):642-50
   PubMed Web of Science ®Google Scholar
• Busse WW, Bateman ED, O’Byrne PM, et al. Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial. Allergy 2014;69(11):1522-30
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002673/WC500157633.pdf
   Google Scholar
• Chopra D, Bhandari B, Wardhan N. Ciclesonide--a novel corticosteroid for the management of asthma. Curr Clin Pharmacol 2012;7(2):73-7
   PubMedGoogle Scholar
• Nave R, Fisher R, Zech K. In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm Drug Dispos 2006;27(4):197-207
   PubMed Web of Science ®Google Scholar
• Nave R, Watz H, Hoffmann H, et al. Deposition and metabolism of inhaled ciclesonide in the human lung. Eur Respir J 2010;36(5):1113-19
   PubMed Web of Science ®Google Scholar
• Dahl R, Engelstatter R, Trebas-Pietraś E, Kuna P. A 24-week comparison of low-dose ciclesonide and fluticasone propionate in mild to moderate asthma. Respir Med 2010;104(8):1121-30
   PubMed Web of Science ®Google Scholar
• Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database Syst Rev 2008(2):CD007031
   PubMed Web of Science ®Google Scholar
• Chiu KC, Chou YL, Hsu JY, et al. Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: a randomised parallel-group study. NPJ Prim Care Respir Med 2014;24:14010
   PubMed Web of Science ®Google Scholar
• Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001;87(5):405-11
   PubMed Web of Science ®Google Scholar
• Price D, Robertson A, Bullen K, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler:a randomized open-label study. BMC Pulm Med 2010;10:1
   PubMed Web of Science ®Google Scholar
• Newton R, Holden NS. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 2007;72(4):799-809
   PubMed Web of Science ®Google Scholar
• De Bosscher K, Haegeman G, Elewaut D. Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 2010;10(4):497-504
   PubMed Web of Science ®Google Scholar
• Schacke H, Zollner TM, Docke WD, et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 2009;158(4):1088-103
   PubMed Web of Science ®Google Scholar
• Lopez FJ, Ardecky RJ, Bebo B, et al. LGD5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo. Endocrinology 2008;149(5):2080-9
   PubMed Web of Science ®Google Scholar
• Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol 2007;275(1-2):98-108
   PubMed Web of Science ®Google Scholar
• Presman DM, Ogara MF, Stortz M, et al. Live cell imaging unveils multiple domain requirements for in vivo dimerization of the glucocorticoid receptor. PLoS Biol 2014;12(3):e1001813
   Google Scholar
• Gauvreau GM, Boulet LP, Leigh R, et al. A nonsteroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses. Am J Respir Crit Care Med 2015;191(2):161-7
   PubMed Web of Science ®Google Scholar
• Uings IJ, Needham D, Matthews J, et al. Discovery of GW870086: a potent anti-inflammatory steroid with a unique pharmacological profile. Br J Pharmacol 2013;169(6):1389-403
   PubMed Web of Science ®Google Scholar
• Bareille P, Hardes K, Donald AC. Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: a randomised, two-way crossover, controlled clinical trial. J Asthma 2013;50(10):1077-82
   PubMed Web of Science ®Google Scholar
• Stamer WD, Hoffman EA, Kurali E, Krauss AH. Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist. GW870086X. Invest Ophthalmol Vis Sci 2013;54(3):2100-7
   PubMed Web of Science ®Google Scholar
• Dolle S, Hielscher N, Bareille PJ, et al. Clinical efficacy and tolerability of a novel selective corticosteroid in atopic dermatitis - two randomised controlled trials. Skin Pharmacol Physiol 2015;28(3):159-66
   PubMed Web of Science ®Google Scholar
• Boulet LP, Lemiere C, Gauvreau G, et al. Safety, pharmacodynamics and pharmacokinetics of TPI 1020 in smokers with asthma. Respir Med 2009;103(8):1159-66
   PubMed Web of Science ®Google Scholar
• Turner Dl, Ferrari N, Ford WR, et al. Bronchoprotection in conscious guinea pigs by budesonide and the NO-donating analogue, TPI 1020, alone and combined with tiotropium or formoterol. Br J Pharmacol 2012;167(3):515-26
   PubMed Web of Science ®Google Scholar
• Norman P. Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1Hindazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423). Expert Opin Ther Pat 2013;23(9):1239-45
   PubMed Web of Science ®Google Scholar
• Baiula M, Bedini A, Baldi J, et al. Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in latephase experimental ocular allergy. Drug Des Devel Ther 2014;8:745-57
   PubMed Web of Science ®Google Scholar
• Baiula M, Sparta A, Bedini A, et al. Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist. Mol Vis 2011;17:3208-23
   PubMed Web of Science ®Google Scholar
• Miner JN, Ardecky B, Benbatoul K, et al. Antiinflammatory glucocorticoid receptor ligand with reduced sideeffects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci USA 2007;104(49):19244-9
   PubMed Web of Science ®Google Scholar
• Yates CM, Brown PJ, Stewart EL, et al. Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists. J Med Chem 2010;53(11):4531-44
   PubMed Web of Science ®Google Scholar
• Gilmore JL, Sheppeck JE2nd, Wang J, et al. Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonists. Bioorg Med Chem Lett 2013;23(19):5448-51
   PubMed Web of Science ®Google Scholar
• Sheppeck JE2nd, Gilmore JL, Xiao HY, et al. Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists. Bioorg Med Chem Lett 2013;23(19):5442-7
   PubMed Web of Science ®Google Scholar
• DiSalvo D, Kuzmich D, Bentzien J, et al. Substituted phenyl as a steroid A-ring mimetic: providing agonist activity to a class of arylsulfonamide nonsteroidal glucocorticoid ligands. Bioorg Med Chem Lett 2013;23(24):6645-9
   PubMed Web of Science ®Google Scholar
• Kuzmich D, Bentzien J, Betageri R, et al. Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists. Bioorg Med Chem Lett 2013;23(24):6640-4
   PubMed Web of Science ®Google Scholar
• Available from: https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/34622
   Google Scholar
• Porsbjerg C, Lund TK, Pedersen L, Backer V. Inflammatory subtypes in asthma are related to airway hyperresponsiveness to mannitol and exhaled NO. J Asthma 2009;46(6):606-12
   PubMed Web of Science ®Google Scholar